Predicting recurrence of respiratory failure in critically ill patients with COVID-19: A preliminary study

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Prolonged corticosteroid therapy and cytomegalovirus infection in patients with severe COVID‐19

“…5 However, we experienced a relapse of respiratory failure, despite dexamethasone administration compliant with the RECOVERY trial. 4,9 Therefore, prolonged systemic corticosteroid therapy is considered a treatment option for selected COVID-19 cases. 31 Although we found no correlations between patient mortality and D-dimer levels, previous studies have reported an association with patient prognosis.…”

“…Occasionally, the duration of systemic corticosteroid therapy requires extension due to recurrent respiratory failure. 9 However, the association of systemic corticosteroid therapy with CMV infection and patient prognosis remains unclear. We aimed to investigate the correlation of CMV infection with the duration of systemic corticosteroid therapy, to evaluate the utility of monitoring CMV infection in patients with COVID-19, and to estimate the maximum duration of systemic corticosteroid therapy without CMV infection.…”

Cytomegalovirus infection in critically ill patients with COVID-19

“…Moreover, these are risk factors for disease recurrence or secondary infections in patients with COVID-19. 1 , 6 , 7 Further, infection with SARS-CoV-2 induces M1 polarisation of macrophages that promote the reactivation of latent CMV; inflammatory cytokines such as tumour necrosis factor-α may be directly associated with CMV reactivation. Importantly, CMV infection may be associated with accelerated immunosenescence, leading to the attrition of naive T cells.…”

Fatal cytomegalovirus pneumonia in a critically ill patient with COVID‐19

“…Therefore, surrogate markers for identifying COVID‐19‐related inflammation are required to avoid unnecessary long‐term administration of immunosuppressive agents. A recent preliminary study suggests that the combination of lymphocyte counts and IgG antibody levels against spike and receptor‐binding domain may help detect remnant COVID‐19‐related inflammation [15].…”